Skip to content
Menu

Citizens Maintains Market Outperform on IRulya Therapeutics, Raises Price Target to $86

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.

Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.

Read at benzinga.com